Network News
Joint Press Release from NCT Heidelberg and Mannheim University Medical Center The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium. […]
read more
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age […]
read more
A new genetic tool helps researchers uncover the logic of gene regulation
Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression Summary The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative […]
read more
New research shows the Golgi complex is involved in DNA repair control
Researchers have discovered a previously unknown layer of control over DNA repair in cells, exerted from outside the nucleus Summary Our DNA is under constant threat. Chemicals, radiation, and the everyday errors of cell division all damage it, and if left unrepaired, this can lead to diseases such as cancer. Cells invest heavily in finding […]
read more
Merck Opens BioReliance® Facility in Darmstadt to Support Drug Product Release in Europe
Merck opens a €25M testing facility at its Darmstadt headquarters, strengthening drug release testing for European biopharmaceutical markets. 16 Jul 2026 | Darmstadt, Germany Merck, a leading science and technology company, today opened a new €25 million BioReliance® testing facility at its global headquarters in Darmstadt, Germany. The facility expands access to commercial drug substance and drug product […]
read more
New software helps researchers decode the cellular architecture of lymphoma
An open-source analysis framework developed by researchers at EMBL, HHU, and other institutions makes it easier to study how cells are organised within tumours, paving the way for new insights into cancer biology Summary How cancer develops and responds to treatment depends not only on the tumour cells themselves but also on the complex ecosystem […]
read more
EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing
The spin-off aims to develop a new generation of precision medicines using epigenome editing to precisely regulate gene expression without altering DNA A newly launched EMBL spin-off, Epitome Therapeutics, aims to translate pioneering research in epigenome editing into a new generation of precision medicines. Co-founded by EMBL Group Leader Jamie Hackett, the company builds on cutting-edge […]
read more
Complex Simulations: New Findings on Proton Transport in Water
International research team simulates motions of a hydrated proton in full quantum detail Complex simulations – the most intricate of their kind to date – reveal how water governs the way protons move through it. They were carried out by an international research team led by scientists of Heidelberg University’s Institute for Physical Chemistry. Using […]
read more
“Every Cell Tells Its Own Story” – Aviv Regev Awarded the 2026 Meyenburg Prize
The 2026 Meyenburg Prize goes to bioinformatician and systems biologist Aviv Regev, head of research at the biotech company Genentech in San Francisco, USA. The scientist is considered a pioneer of single-cell genomics, a method that allows for the high-resolution measurement and analysis of gene activity in individual cells—a field of research that has fundamentally […]
read more
